{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:24:22Z","timestamp":1787178262405,"version":"build-2736575974"},"reference-count":202,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":230,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sinai University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson\u2019s disease (PD) is increasingly recognized as a disorder of glial dysfunction, wherein astrocytes transition from homeostatic supporters to active drivers of neurodegeneration. This review synthesizes recent evidence to propose a novel dual-pathway failure model in which internalized alpha-synuclein orchestrates a self-amplifying cycle of astrocytic toxicity. Pathological alpha-synuclein simultaneously suppresses key cytoprotective systems, the Nrf2-mediated antioxidant response and TFEB-regulated autophagy-lysosomal degradation, while hyperactivating neuroinflammatory signaling via NF-\u03baB\/MAPK and the recently implicated cGAS-STING axis, triggered by mitochondrial DNA release. This imbalance fosters chronic oxidative stress, proteostatic collapse, and sustained neuroinflammation. Ferroptosis, a form of necrotic cell death characterized by iron dependency and lipid peroxidation, may represent a likely downstream consequence of astrocytic death when protective failure (Nrf2\/TFEB suppression) overlaps with toxic activation (cGAS-STING\/NF-\u03baB signaling) and disturbances in iron and lipid homeostasis. The concurrent failure of antioxidant defenses and the buildup of labile iron and peroxidizable lipids could establish a conducive environment for ferroptotic membrane rupture, potentially resulting in secondary neuronal damage. This gliocentric model reframes PD pathogenesis as a feed-forward loop of neurotoxicity originating in astrocytic reprogramming. Therapeutically, breaking this cycle via STING inhibition, Nrf2\/TFEB activation, and anti-ferroptotic agents represents a promising but still experimental avenue for intervention aimed at restoring astrocyte homeostasis and potentially halting neurodegeneration. However, it is critical to note that the evidence supporting these approaches is derived almost exclusively from preclinical models, with no approved therapies targeting these astrocytic pathways currently available for PD patients.<\/jats:p>","DOI":"10.1007\/s12035-026-06101-6","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T21:35:02Z","timestamp":1787175302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual-Pathway Astrocyte Failure in Parkinson\u2019s Disease: Therapeutic Targeting of Nrf2\/TFEB Suppression and cGAS-STING\/Ferroptosis Activation"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4747-8549","authenticated-orcid":false,"given":"Ahmed M.","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"6101_CR1","doi-asserted-by":"publisher","unstructured":"van Wamelen DJ, Sringean J, Trivedi D, Carroll CB, Schrag AE, Odin P, Antonini A, Bloem BR, et al. (2021) Digital health technology for non-motor symptoms in people with Parkinson\u2019s disease: futile or future? Parkinsonism Relat Disord 89:186\u2013194. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.07.032","DOI":"10.1016\/j.parkreldis.2021.07.032"},{"key":"6101_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S12602-026-11014-W","volume":"2026","author":"NH Almohmadi","year":"2026","unstructured":"Almohmadi NH, Al-kuraishy HM, Hussein KS, Turkistani AM, Yousef FM, Al-Gareeb AI, Abdelaziz AM, Elewa YHA, et al. (2026) The gut-brain axis: a critical link between type 2 diabetes and Parkinson\u2019s disease. Probiotics Antimicrob Proteins 2026:1\u201325. https:\/\/doi.org\/10.1007\/S12602-026-11014-W","journal-title":"Probiotics Antimicrob Proteins"},{"key":"6101_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloemd BR (2018) The emerging evidence of the Parkinson pandemic. J Parkinsons Dis 8:S3\u2013S8. https:\/\/doi.org\/10.3233\/JPD-181474","journal-title":"J Parkinsons Dis"},{"key":"6101_CR4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.4103\/1673-5374.300980","volume":"16","author":"J Dorszewska","year":"2021","unstructured":"Dorszewska J, Kowalska M, Prendecki M, Piekut T, Koz\u0142owska J, Kozubski W (2021) Oxidative stress factors in Parkinson\u2019s disease. Neural Regen Res 16:1383\u20131391","journal-title":"Neural Regen Res"},{"key":"6101_CR5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/brain\/awab446","volume":"145","author":"S Smajic","year":"2022","unstructured":"Smajic S, Prada-Medina CA, Landoulsi Z, Ghelfi J, Delcambre S, Dietrich C, Jarazo J, Henck J, et al. (2022) Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain 145:964\u2013978. https:\/\/doi.org\/10.1093\/brain\/awab446","journal-title":"Brain"},{"key":"6101_CR6","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","volume":"132","author":"MT Hayes","year":"2019","unstructured":"Hayes MT (2019) Parkinson\u2019s disease and parkinsonism. Am J Med 132:802\u2013807. https:\/\/doi.org\/10.1016\/j.amjmed.2019.03.001","journal-title":"Am J Med"},{"key":"6101_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.776847","volume":"9","author":"Z Ou","year":"2021","unstructured":"Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z (2021) Global trends in the incidence, prevalence, and years lived with disability of Parkinson\u2019s disease in 204 countries\/territories from 1990 to 2019. Front Public Health 9:776847. https:\/\/doi.org\/10.3389\/fpubh.2021.776847","journal-title":"Front Public Health"},{"key":"6101_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-018-0058-0","volume":"4","author":"C Marras","year":"2018","unstructured":"Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, Abbott RD, Savica R, et al. (2018) Prevalence of Parkinson\u2019s disease across North America. NPJ Park Dis 4:21. https:\/\/doi.org\/10.1038\/s41531-018-0058-0","journal-title":"NPJ Park Dis"},{"key":"6101_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11010170","volume":"11","author":"S Takahashi","year":"2022","unstructured":"Takahashi S, Mashima K (2022) Neuroprotection and disease modification by astrocytes and microglia in Parkinson disease. Antioxidants (Basel, Switzerland) 11:170. https:\/\/doi.org\/10.3390\/antiox11010170","journal-title":"Antioxidants (Basel, Switzerland)"},{"key":"6101_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41583-022-00641-1","volume":"24","author":"AN Brandebura","year":"2023","unstructured":"Brandebura AN, Paumier A, Onur TS, Allen NJ (2023) Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders. Nat Rev Neurosci 24:23\u201339. https:\/\/doi.org\/10.1038\/s41583-022-00641-1","journal-title":"Nat Rev Neurosci"},{"key":"6101_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.chaos.2024.115154","volume":"185","author":"Z Cao","year":"2024","unstructured":"Cao Z, Du L, Zhang H, Shen Z, Deng Z (2024) Double-edged effect of astrocyte in the transition of physiopathological states in Parkinson\u2019s disease. Chaos Solitons Fractals 185:115154. https:\/\/doi.org\/10.1016\/j.chaos.2024.115154","journal-title":"Chaos Solitons Fractals"},{"key":"6101_CR12","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/CELLS10081850","volume":"10","author":"Q Guo","year":"2021","unstructured":"Guo Q, Wang B, Wang X, Smith WW, Zhu Y, Liu Z (2021) Activation of Nrf2 in astrocytes suppressed PD-like phenotypes via antioxidant and autophagy pathways in rat and Drosophila models. Cells 10:1850. https:\/\/doi.org\/10.3390\/CELLS10081850","journal-title":"Cells"},{"key":"6101_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/J.TINS.2016.02.002","volume":"39","author":"H Martini-Stoica","year":"2016","unstructured":"Martini-Stoica H, Xu Y, Ballabio A, Zheng H (2016) The autophagy\u2013lysosomal pathway in neurodegeneration: a TFEB perspective. Trends Neurosci 39:221. https:\/\/doi.org\/10.1016\/J.TINS.2016.02.002","journal-title":"Trends Neurosci"},{"key":"6101_CR14","doi-asserted-by":"publisher","unstructured":"Luo y, Zhao Z, Hu X (2023) cGAS-STING-mediated inflammation and neurodegeneration as a strategy for the treatment of neurodegenerative diseases: role of mtDNA-cGAS-STING in neurodegenerative diseases, Acta Biochim. Biophys. Sin. (Shanghai). 56:148. https:\/\/doi.org\/10.3724\/ABBS.2023258","DOI":"10.3724\/ABBS.2023258"},{"key":"6101_CR15","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1038\/S41418-023-01216-Y","volume":"30","author":"SY Jiang","year":"2023","unstructured":"Jiang SY, Tian T, Yao H, Xia XM, Wang C, Cao L, Hu G, Du RH, et al. (2023) The cGAS-STING-YY1 axis accelerates progression of neurodegeneration in a mouse model of Parkinson\u2019s disease via LCN2-dependent astrocyte senescence. Cell Death Differ 30:2280. https:\/\/doi.org\/10.1038\/S41418-023-01216-Y","journal-title":"Cell Death Differ"},{"key":"6101_CR16","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3390\/ANTIOX14111276\/S1","volume":"14","author":"Y Mun","year":"2025","unstructured":"Mun Y, Kim J, Choi YJ, Lee BH (2025) cGAS\u2013STING\u2013NF-\u03baB axis mediates rotenone-induced NLRP3 inflammasome activation through mitochondrial DNA release. Antioxidants (Basel) 14:1276. https:\/\/doi.org\/10.3390\/ANTIOX14111276\/S1","journal-title":"Antioxidants (Basel)"},{"key":"6101_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/S12964-023-01274-2","volume":"21","author":"J Shao","year":"2023","unstructured":"Shao J, Meng Y, Yuan K, Wu Q, Zhu S, Li Y, Wu P, Zheng J, et al. (2023) RU.521 mitigates subarachnoid hemorrhage-induced brain injury via regulating microglial polarization and neuroinflammation mediated by the cGAS\/STING\/NF-\u03baB pathway. Cell Commun Signal 21:264. https:\/\/doi.org\/10.1186\/S12964-023-01274-2","journal-title":"Cell Commun Signal"},{"key":"6101_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/S12035-025-05542-9","volume":"63","author":"Z Gong","year":"2025","unstructured":"Gong Z, Guo D, Lin Y, Liu Z, Lv M, Liu X, Sun M, Wang L, et al. (2025) Deciphering ferroptosis-related astrocyte subpopulations and diagnostic biomarkers in Parkinson\u2019s disease through RNA transcriptomics. Mol Neurobiol 63:221. https:\/\/doi.org\/10.1007\/S12035-025-05542-9","journal-title":"Mol Neurobiol"},{"key":"6101_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/FNINS.2020.00267\/FULL","volume":"14","author":"X Song","year":"2020","unstructured":"Song X, Long D (2020) Nrf2 and ferroptosis: a new research direction for neurodegenerative diseases. Front Neurosci 14:484266. https:\/\/doi.org\/10.3389\/FNINS.2020.00267\/FULL","journal-title":"Front Neurosci"},{"key":"6101_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/J.MOLMED.2022.02.003","volume":"28","author":"ZL Wang","year":"2022","unstructured":"Wang ZL, Yuan L, Li W, Li JY (2022) Ferroptosis in Parkinson\u2019s disease: glia\u2013neuron crosstalk. Trends Mol Med 28:258\u2013269. https:\/\/doi.org\/10.1016\/J.MOLMED.2022.02.003","journal-title":"Trends Mol Med"},{"key":"6101_CR21","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.65.8.16","volume":"65","author":"M Tanaka","year":"2024","unstructured":"Tanaka M, Yasuda H, Nakamura S, Shimazawa M (2024) H-151, a selective STING inhibitor, has potential as a treatment for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 65:16. https:\/\/doi.org\/10.1167\/iovs.65.8.16","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6101_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/FNCEL.2021.787258\/FULL","volume":"15","author":"S Saha","year":"2022","unstructured":"Saha S, Buttari B, Profumo E, Tucci P, Saso L (2022) A perspective on Nrf2 signaling pathway for neuroinflammation: a potential therapeutic target in Alzheimer\u2019s and Parkinson\u2019s diseases. Front Cell Neurosci 15:787258. https:\/\/doi.org\/10.3389\/FNCEL.2021.787258\/FULL","journal-title":"Front Cell Neurosci"},{"key":"6101_CR23","doi-asserted-by":"publisher","unstructured":"Portbury SD, Hare DJ, Sgambelloni C, Perronnes K, Portbury AJ, Finkelstein DI, Adlard PA (2017) Trehalose improves cognition in the transgenic Tg2576 mouse model of Alzheimer\u2019s disease. Journal of Alzheimer\u2019s Disease 60:549\u2013560. https:\/\/doi.org\/10.3233\/JAD-170322;ISSUE:ISSUE:DOI","DOI":"10.3233\/JAD-170322;ISSUE:ISSUE:DOI"},{"key":"6101_CR24","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1074\/jbc.M609532200","volume":"282","author":"S Sarkar","year":"2007","unstructured":"Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC (2007) Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and \u03b1-synuclein. J Biol Chem 282:5641\u20135652. https:\/\/doi.org\/10.1074\/jbc.M609532200","journal-title":"J Biol Chem"},{"key":"6101_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/J.TCB.2015.10.014","volume":"26","author":"WS Yang","year":"2015","unstructured":"Yang WS, Stockwell BR (2015) Ferroptosis: death by lipid peroxidation. Trends Cell Biol 26:165. https:\/\/doi.org\/10.1016\/J.TCB.2015.10.014","journal-title":"Trends Cell Biol"},{"key":"6101_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/J.JARE.2024.12.028","volume":"76","author":"L Ding","year":"2024","unstructured":"Ding L, Zhang R, Du W, Wang Q, Pei D (2024) The role of cGAS-STING signaling pathway in ferroptosis. J Adv Res 76:219. https:\/\/doi.org\/10.1016\/J.JARE.2024.12.028","journal-title":"J Adv Res"},{"key":"6101_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEUINT.2024.105774","volume":"178","author":"Z Cyske","year":"2024","unstructured":"Cyske Z, Gaffke L, Rintz E, Wi\u015bniewska K, W\u0119grzyn G, Pierzynowska K (2024) Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease. Neurochem Int 178:105774. https:\/\/doi.org\/10.1016\/J.NEUINT.2024.105774","journal-title":"Neurochem Int"},{"key":"6101_CR28","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1007\/s12031-021-01836-4","volume":"71","author":"H Cui","year":"2021","unstructured":"Cui H, Wang W, Zheng X, Xia D, Liu H, Qin C, Tian H, Teng J (2021) Decreased AQP4 expression aggravates \u0251-synuclein pathology in Parkinson\u2019s disease mice, possibly via impaired glymphatic clearance. J Mol Neurosci 71:2500\u20132513. https:\/\/doi.org\/10.1007\/s12031-021-01836-4","journal-title":"J Mol Neurosci"},{"key":"6101_CR29","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1097\/00004647-200411000-00008","volume":"24","author":"L Hertz","year":"2004","unstructured":"Hertz L (2004) The astrocyte-neuron lactate shuttle: a challenge of a challenge. J Cereb Blood Flow Metab 24:1241\u20131248. https:\/\/doi.org\/10.1097\/00004647-200411000-00008","journal-title":"J Cereb Blood Flow Metab"},{"key":"6101_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.668517","volume":"12","author":"P Mulica","year":"2021","unstructured":"Mulica P, Gr\u00fcnewald A, Pereira SL (2021) Astrocyte-neuron metabolic crosstalk in neurodegeneration: a mitochondrial perspective. Front. Endocrinol. (Lausanne) 12:668517. https:\/\/doi.org\/10.3389\/fendo.2021.668517","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"6101_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2022.109102","volume":"220","author":"AN Strat","year":"2022","unstructured":"Strat AN, Kirschner A, Yoo H, Singh A, Bagu\u00e9 T, Li H, Herberg S, Ganapathy PS (2022) Engineering a 3D hydrogel system to study optic nerve head astrocyte morphology and behavior. Exp Eye Res 220:109102. https:\/\/doi.org\/10.1016\/j.exer.2022.109102","journal-title":"Exp Eye Res"},{"key":"6101_CR32","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4149\/BLL_2024_119","volume":"125","author":"I Sivakova","year":"2024","unstructured":"Sivakova I, Polak S, Perzelova A (2024) Problematic visualization of human protoplasmic astrocytes immunohistochemical stains. Bratisl. Lek. Listy 125:780\u2013784. https:\/\/doi.org\/10.4149\/BLL_2024_119","journal-title":"Bratisl. Lek. Listy"},{"key":"6101_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11064-019-02926-x","volume":"46","author":"S K\u00f6hler","year":"2021","unstructured":"K\u00f6hler S, Winkler U, Hirrlinger J (2021) Heterogeneity of astrocytes in grey and white matter. Neurochem Res 46:3\u201314. https:\/\/doi.org\/10.1007\/s11064-019-02926-x","journal-title":"Neurochem Res"},{"key":"6101_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11110732","volume":"11","author":"CDB Murat","year":"2021","unstructured":"Murat CDB, Garc\u00eda-C\u00e1ceres C (2021) Astrocyte gliotransmission in the regulation of systemic metabolism. Metabolites 11:732. https:\/\/doi.org\/10.3390\/metabo11110732","journal-title":"Metabolites"},{"key":"6101_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2022.102331","volume":"217","author":"JV Andersen","year":"2022","unstructured":"Andersen JV, Schousboe A, Verkhratsky A (2022) Astrocyte energy and neurotransmitter metabolism in Alzheimer\u2019s disease: integration of the glutamate\/GABA-glutamine cycle. Prog Neurobiol 217:102331. https:\/\/doi.org\/10.1016\/j.pneurobio.2022.102331","journal-title":"Prog Neurobiol"},{"key":"6101_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.1037641","author":"AO Cuellar-Santoyo","year":"2023","unstructured":"Cuellar-Santoyo AO, Ruiz-Rodr\u00edguez VM, Mares-Barbosa TB, Patr\u00f3n-Soberano A, Howe AG, Portales-P\u00e9rez DP, Miquelaj\u00e1uregui Graf A, Estrada-S\u00e1nchez AM (2023) Revealing the contribution of astrocytes to glutamatergic neuronal transmission. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2022.1037641","journal-title":"Front Cell Neurosci"},{"key":"6101_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.665334","volume":"12","author":"MRS Sandhu","year":"2021","unstructured":"Sandhu MRS, Gruenbaum BF, Gruenbaum SE, Dhaher R, Deshpande K, Funaro MC, Lee TSW, Zaveri HP, et al. (2021) Astroglial glutamine synthetase and the pathogenesis of mesial temporal lobe epilepsy. Front Neurol 12:665334. https:\/\/doi.org\/10.3389\/fneur.2021.665334","journal-title":"Front Neurol"},{"key":"6101_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cells13020150","volume":"13","author":"G Schiera","year":"2024","unstructured":"Schiera G, Di Liegro CM, Schir\u00f2 G, Sorbello G, Di Liegro I (2024) Involvement of astrocytes in the formation, maintenance, and function of the blood\u2013brain barrier. Cells 13:150. https:\/\/doi.org\/10.3390\/cells13020150","journal-title":"Cells"},{"key":"6101_CR39","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00422-024-00994-z","volume":"118","author":"DW Garcia","year":"2024","unstructured":"Garcia DW, Jacquir S (2024) Astrocyte-mediated neuronal irregularities and dynamics: the complexity of the tripartite synapse. Biol Cybern 118:249\u2013266. https:\/\/doi.org\/10.1007\/s00422-024-00994-z","journal-title":"Biol Cybern"},{"key":"6101_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1042\/EBC20220075","volume":"67","author":"A Almeida","year":"2023","unstructured":"Almeida A, Jimenez-Blasco D, Bola\u00f1os JP (2023) Cross-talk between energy and redox metabolism in astrocyte-neuron functional cooperation. Essays Biochem 67:17\u201326. https:\/\/doi.org\/10.1042\/EBC20220075","journal-title":"Essays Biochem"},{"key":"6101_CR41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neures.2023.02.001","volume":"197","author":"M Albini","year":"2023","unstructured":"Albini M, Krawczun-Rygmaczewska A, Cesca F (2023) Astrocytes and brain-derived neurotrophic factor (BDNF). Neurosci Res 197:42\u201351","journal-title":"Neurosci Res"},{"key":"6101_CR42","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s11064-022-03773-z","volume":"48","author":"L Henning","year":"2023","unstructured":"Henning L, Unichenko P, Bedner P, Steinh\u00e4user C, Henneberger C (2023) Overview article astrocytes as initiators of epilepsy. Neurochem Res 48:1091\u20131099. https:\/\/doi.org\/10.1007\/s11064-022-03773-z","journal-title":"Neurochem Res"},{"key":"6101_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.814285","volume":"13","author":"S Wang","year":"2022","unstructured":"Wang S, Wang B, Shang D, Zhang K, Yan X, Zhang X (2022) Ion channel dysfunction in astrocytes in neurodegenerative diseases. Front Physiol 13:814285. https:\/\/doi.org\/10.3389\/fphys.2022.814285","journal-title":"Front Physiol"},{"key":"6101_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.662017","volume":"12","author":"O Barca-Mayo","year":"2021","unstructured":"Barca-Mayo O, L\u00f3pez M (2021) Astrocyte clocks and glucose homeostasis. Front Endocrinol (Lausanne) 12:662017. https:\/\/doi.org\/10.3389\/fendo.2021.662017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6101_CR45","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.4c00614","author":"S Al-Jaf","year":"2025","unstructured":"Al-Jaf S, Soliman AY, El-Yazbi AF, Abd-Elrahman KS (2025) Unveiling the interplay: neurovascular coupling, astrocytes and G protein-coupled receptors in Alzheimer\u2019s disease. ACS Pharmacol Transl Sci. https:\/\/doi.org\/10.1021\/acsptsci.4c00614","journal-title":"ACS Pharmacol Transl Sci"},{"key":"6101_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/jnc.15941","volume":"167","author":"MB Cieri","year":"2023","unstructured":"Cieri MB, Villarreal A, Gomez-Cuautle DD, Mailing I, Ramos AJ (2023) Progression of reactive gliosis and astroglial phenotypic changes following stab wound-induced traumatic brain injury in mice. J Neurochem 167:183\u2013203. https:\/\/doi.org\/10.1111\/jnc.15941","journal-title":"J Neurochem"},{"key":"6101_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/J.HELIYON.2025.E42051","volume":"11","author":"Z Gong","year":"2025","unstructured":"Gong Z, Guo D, Lin Y, Liu Z, Lv M, Liu X, Yao Y, Wang S, et al. (2025) A single-cell transcriptome analysis reveals astrocyte heterogeneity and identifies CHI3L1 as a diagnostic biomarker in Parkinson\u2019s disease. Heliyon 11:e42051. https:\/\/doi.org\/10.1016\/J.HELIYON.2025.E42051","journal-title":"Heliyon"},{"issue":"1","key":"6101_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41420-025-02812-2","volume":"11","author":"Y Li","year":"2025","unstructured":"Li Y, Hao J, Wang W, Su Z, Tian X, Wang H, Liu Q, Gao D, Geng D, Wang L (2025) Inhibition of astrocyte BMP signaling alleviates neuroinflammation in experimental models of Parkinson\u2019s disease. Cell Death Discovery 11(1):11\u2013528. https:\/\/doi.org\/10.1038\/s41420-025-02812-2","journal-title":"Cell Death Discovery"},{"key":"6101_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-021-00265-y","volume":"10","author":"C Wang","year":"2021","unstructured":"Wang C, Yang T, Liang M, Xie J, Song N (2021) Astrocyte dysfunction in Parkinson\u2019s disease: from the perspectives of transmitted \u03b1-synuclein and genetic modulation. Transl Neurodegener 10:1\u20137. https:\/\/doi.org\/10.1186\/s40035-021-00265-y","journal-title":"Transl Neurodegener"},{"key":"6101_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/S10787-026-02176-8","author":"Z Al-Qahtani","year":"2026","unstructured":"Al-Qahtani Z, Al-kuraishy HM, Al-Gareeb AI, Albuhadily AK, Abdelaziz AM, Alruwaili M, Batiha G-S (2026) Astrocytic dysfunction in Parkinson\u2019s disease pathogenesis: focusing on alpha-synuclein. Inflammopharmacology. https:\/\/doi.org\/10.1007\/S10787-026-02176-8","journal-title":"Inflammopharmacology"},{"key":"6101_CR51","doi-asserted-by":"publisher","first-page":"8618","DOI":"10.1523\/JNEUROSCI.0954-20.2020","volume":"40","author":"T Tsunemi","year":"2020","unstructured":"Tsunemi T, Ishiguro Y, Yoroisaka A, Valdez C, Miyamoto K, Ishikawa K, Saiki S, Akamatsu W, et al. (2020) Astrocytes protect human dopaminergic neurons from \u03b1-synuclein accumulation and propagation. J Neurosci 40:8618\u20138628. https:\/\/doi.org\/10.1523\/JNEUROSCI.0954-20.2020","journal-title":"J Neurosci"},{"key":"6101_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPHAR.2025.177646","volume":"998","author":"A Al-Dhahi","year":"2025","unstructured":"Al-Dhahi A, Al-kuraishy HM, Albuhadily AK, Al-Gareeb AI, Abdelaziz AM, Alexiou A, Papadakis M, Alruwaili M, et al. (2025) The possible role of neurogenesis activators in temporal lobe epilepsy: state of art and future perspective. Eur J Pharmacol 998:177646. https:\/\/doi.org\/10.1016\/J.EJPHAR.2025.177646","journal-title":"Eur J Pharmacol"},{"key":"6101_CR53","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.toxlet.2020.06.016","volume":"331","author":"Y Meng","year":"2020","unstructured":"Meng Y, Ding J, Li C, Fan H, He Y, Qiu P (2020) Transfer of pathological \u03b1-synuclein from neurons to astrocytes via exosomes causes inflammatory responses after METH exposure. Toxicol Lett 331:188\u2013199. https:\/\/doi.org\/10.1016\/j.toxlet.2020.06.016","journal-title":"Toxicol Lett"},{"key":"6101_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-015-0042-0","volume":"4","author":"Q Wang","year":"2015","unstructured":"Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target. Transl Neurodegener 4:19. https:\/\/doi.org\/10.1186\/s40035-015-0042-0","journal-title":"Transl Neurodegener"},{"key":"6101_CR55","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kam TI, Panicker N, Kim S, Oh Y, Park JS, Kwon SH, Park YJ, et al. (2018) Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease. Nat Med 24:931\u2013938. https:\/\/doi.org\/10.1038\/s41591-018-0051-5","journal-title":"Nat Med"},{"key":"6101_CR56","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2020.08.012","volume":"108","author":"M Linnerbauer","year":"2020","unstructured":"Linnerbauer M, Wheeler MA, Quintana FJ (2020) Astrocyte crosstalk in CNS inflammation. Neuron 108:608\u2013622. https:\/\/doi.org\/10.1016\/j.neuron.2020.08.012","journal-title":"Neuron"},{"key":"6101_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104647","volume":"134","author":"E Aflaki","year":"2020","unstructured":"Aflaki E, Stubblefield BK, McGlinchey RP, McMahon B, Ory DS, Sidransky E (2020) A characterization of Gaucher iPS-derived astrocytes: potential implications for Parkinson\u2019s disease. Neurobiol Dis 134:104647. https:\/\/doi.org\/10.1016\/j.nbd.2019.104647","journal-title":"Neurobiol Dis"},{"key":"6101_CR58","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-018-0276-2","volume":"13","author":"C Kim","year":"2018","unstructured":"Kim C, Spencer B, Rockenstein E, Yamakado H, Mante M, Adame A, Fields JA, Masliah D, et al. (2018) Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating \u03b1-synuclein transmission and neuroinflammation. Mol Neurodegener 13:43. https:\/\/doi.org\/10.1186\/s13024-018-0276-2","journal-title":"Mol Neurodegener"},{"key":"6101_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71329-8","volume":"10","author":"TM Sonninen","year":"2020","unstructured":"Sonninen TM, H\u00e4m\u00e4l\u00e4inen RH, Koskuvi M, Oksanen M, Shakirzyanova A, Wojciechowski S, Puttonen K, Naumenko N, et al. (2020) Metabolic alterations in Parkinson\u2019s disease astrocytes. Sci Rep 10:14474. https:\/\/doi.org\/10.1038\/s41598-020-71329-8","journal-title":"Sci Rep"},{"key":"6101_CR60","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1124\/mol.118.112631","volume":"94","author":"KA Popichak","year":"2018","unstructured":"Popichak KA, Hammond SL, Moreno JA, Afzali MF, Backos DS, Slayden RD, Safe S, Tjalkens RB (2018) Compensatory expression of NuR77 and NURR1 regulates NF-KB\u2013dependent inflammatory signaling in astrocytes. Mol Pharmacol 94:1174\u20131186. https:\/\/doi.org\/10.1124\/mol.118.112631","journal-title":"Mol Pharmacol"},{"key":"6101_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2025.114692","volume":"156","author":"AM Abdelaziz","year":"2025","unstructured":"Abdelaziz AM (2025) Alpha-Synuclein drives NURR1 and NLRP3 Inflammasome dysregulation in Parkinson\u2019s disease: from pathogenesis to potential therapeutic strategies. Int Immunopharmacol 156:114692. https:\/\/doi.org\/10.1016\/J.INTIMP.2025.114692","journal-title":"Int Immunopharmacol"},{"key":"6101_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1302-6","volume":"15","author":"RH Du","year":"2018","unstructured":"Du RH, Zhou Y, Xia ML, Lu M, Ding JH, Hu G (2018) \u03b1-Synuclein disrupts the anti-inflammatory role of Drd2 via interfering \u03b2-arrestin2-TAB1 interaction in astrocytes. J Neuroinflammation 15:258. https:\/\/doi.org\/10.1186\/s12974-018-1302-6","journal-title":"J Neuroinflammation"},{"key":"6101_CR63","doi-asserted-by":"publisher","first-page":"9248","DOI":"10.1523\/JNEUROSCI.1731-12.2012","volume":"32","author":"X Lin","year":"2012","unstructured":"Lin X, Parisiadou L, Sgobio C, Liu G, Yu J, Sun L, Shim H, Gu XL, et al. (2012) Conditional expression of Parkinson\u2019s disease-related mutant \u03b1-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J Neurosci 32:9248\u20139264. https:\/\/doi.org\/10.1523\/JNEUROSCI.1731-12.2012","journal-title":"J Neurosci"},{"key":"6101_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2024.113839","author":"AM Abdelaziz","year":"2024","unstructured":"Abdelaziz AM, Rasheed NOA, Zaki HF, Salem HA, El-Sayed RM (2024) Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through targeting the NLRP3\/Nurr1\/GSK-3\u03b2\/SIRT3 pathway and autophagy modulation in rotenone-lesioned rats. Int Immunopharmacol. https:\/\/doi.org\/10.1016\/J.INTIMP.2024.113839","journal-title":"Int Immunopharmacol"},{"key":"6101_CR65","doi-asserted-by":"publisher","first-page":"8756","DOI":"10.1073\/pnas.1509742112","volume":"112","author":"CH Kim","year":"2015","unstructured":"Kim CH, Han BS, Moon J, Kim DJ, Shin J, Rajan S, Nguyen QT, Sohn M, et al. (2015) Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson\u2019s disease. Proc Natl Acad Sci U S A 112:8756\u20138761. https:\/\/doi.org\/10.1073\/pnas.1509742112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6101_CR66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1502740112","volume":"112","author":"NM Urs","year":"2015","unstructured":"Urs NM, Bido S, Peterson SM, Daigle TL, Bass CE, Gainetdinov RR, Bezard E, Caron MG (2015) Targeting \u03b2-arrestin2 in the treatment of l-DOPA- -induced dyskinesia in Parkinson\u2019s disease. Proc Natl Acad Sci U S A 112:E2517-26","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6101_CR67","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12974-020-01776-7","volume":"17","author":"J Rostami","year":"2020","unstructured":"Rostami J, Fotaki G, Sirois J, Mzezewa R, Bergstr\u00f6m J, Essand M, Healy L, Erlandsson A (2020) Astrocytes have the capacity to act as antigen-presenting cells in the Parkinson\u2019s disease brain. J Neuroinflammation 17:119. https:\/\/doi.org\/10.1186\/s12974-020-01776-7","journal-title":"J Neuroinflammation"},{"key":"6101_CR68","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10863-019-09798-4","volume":"51","author":"LP Dolgacheva","year":"2019","unstructured":"Dolgacheva LP, Berezhnov AV, Fedotova EI, Zinchenko VP, Abramov AY (2019) Role of DJ-1 in the mechanism of pathogenesis of Parkinson\u2019s disease. J Bioenerg Biomembr 51:175\u2013188. https:\/\/doi.org\/10.1007\/s10863-019-09798-4","journal-title":"J Bioenerg Biomembr"},{"key":"6101_CR69","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/brain\/awh054","volume":"127","author":"R Bandopadhyay","year":"2004","unstructured":"Bandopadhyay R, Kingsbury AE, Cookson MR, Reid AR, Evans IM, Hope AD, Pittman AM, Lashley T, et al. (2004) The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson\u2019s disease. Brain 127:420\u2013430. https:\/\/doi.org\/10.1093\/brain\/awh054","journal-title":"Brain"},{"key":"6101_CR70","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1096\/fj.08-125153","volume":"23","author":"J Waak","year":"2009","unstructured":"Waak J, Weber SS, Waldenmaier A, G\u00f6rner K, Alunni-Fabbroni M, Schell H, Vogt-Weisenhorn D, Pham TT, et al. (2009) Regulation of astrocyte inflammatory responses by the Parkinson\u2019s disease-associated gene DJ-1. FASEB J 23:2478\u20132489. https:\/\/doi.org\/10.1096\/fj.08-125153","journal-title":"FASEB J"},{"key":"6101_CR71","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/glia.23828","volume":"68","author":"DJ Choi","year":"2020","unstructured":"Choi DJ, Yang H, Gaire S, Lee KA, An J, Kim BG, Jou I, Park SM, et al. (2020) Critical roles of astrocytic-CCL2-dependent monocyte infiltration in a DJ-1 knockout mouse model of delayed brain repair. Glia 68:2086\u20132101. https:\/\/doi.org\/10.1002\/glia.23828","journal-title":"Glia"},{"key":"6101_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2025.156983","volume":"193","author":"SM Alshahrani","year":"2025","unstructured":"Alshahrani SM, Al-Kuraishy HM, Albuhadily AK, Al-Gareeb AI, Abdelaziz AM, Alexiou A, Papadakis M, Alruwaili M, et al. (2025) GDF15 upregulation in Parkinson\u2019s disease: compensatory mechanisms and causal insights. Cytokine 193:156983. https:\/\/doi.org\/10.1016\/j.cyto.2025.156983","journal-title":"Cytokine"},{"key":"6101_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/S10072-025-08679-6","author":"BA Alsfouk","year":"2026","unstructured":"Alsfouk BA, Al-Kuraishy HM, Al-Gareeb AI, Abdelaziz AM, Ismail A, Alkazmi LM, Alexiou A, Papadakis M, et al. (2026) The potential role of COX-2\/PGs signaling pathway in epileptogenesis and associated neuroinflammation: collusions or serendipity. Neurol Sci. https:\/\/doi.org\/10.1007\/S10072-025-08679-6","journal-title":"Neurol Sci"},{"issue":"13","key":"6101_CR74","doi-asserted-by":"publisher","DOI":"10.1101\/2024.11.13.623442","volume":"11","author":"A Dwamena","year":"2024","unstructured":"Dwamena A, Asadi Y, Gilstrap E, Wang H (2024) Impaired proteasome induces mitochondrial DNA release to activate the cGAS-STING signaling pathway and cause necroptosis in mouse brain. BioRxiv. 11(13):623442. https:\/\/doi.org\/10.1101\/2024.11.13.623442","journal-title":"BioRxiv."},{"key":"6101_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/J.NBD.2024.106710","volume":"202","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zou M, Wu H, Zhu J, Jin T (2024) The cGAS-STING pathway drives neuroinflammation and neurodegeneration via cellular and molecular mechanisms in neurodegenerative diseases. Neurobiol Dis 202:106710. https:\/\/doi.org\/10.1016\/J.NBD.2024.106710","journal-title":"Neurobiol Dis"},{"key":"6101_CR76","doi-asserted-by":"publisher","DOI":"10.1111\/CNS.14671;PAGE:STRING:ARTICLE\/CHAPTER","volume":"30","author":"X Guo","year":"2024","unstructured":"Guo X, Yang L, Wang J, Wu Y, Li Y, Du L, Li L, Fang Z, et al. (2024) The cytosolic DNA-sensing cGAS\u2013STING pathway in neurodegenerative diseases. CNS Neurosci Ther 30:e14671. https:\/\/doi.org\/10.1111\/CNS.14671;PAGE:STRING:ARTICLE\/CHAPTER","journal-title":"CNS Neurosci Ther"},{"issue":"2013","key":"6101_CR77","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/SCIENCE.1232458","volume":"339","author":"L Sun","year":"1979","unstructured":"Sun L, Wu J, Du F, Chen X, Chen ZJ (1979) Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339(2013):786\u2013791. https:\/\/doi.org\/10.1126\/SCIENCE.1232458","journal-title":"Science"},{"key":"6101_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2026.157143","volume":"202","author":"E Manni","year":"2026","unstructured":"Manni E, Al-Kuraishy HM, Hussain NR, Abdelaziz AM, Batiha GES (2026) The IGF-1 senescence switch: a biphasic model for SASP-driven aging and precision senomodulation. Cytokine 202:157143. https:\/\/doi.org\/10.1016\/j.cyto.2026.157143","journal-title":"Cytokine"},{"key":"6101_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2024.107063","volume":"201","author":"X He","year":"2024","unstructured":"He X, Wedn A, Wang J, Gu Y, Liu H, Zhang J, Lin Z, Zhou R, et al. (2024) IUPHAR ECR review: the cGAS-STING pathway: novel functions beyond innate immune and emerging therapeutic opportunities. Pharmacol Res 201:107063. https:\/\/doi.org\/10.1016\/J.PHRS.2024.107063","journal-title":"Pharmacol Res"},{"key":"6101_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/SMSC.202500152","volume":"5","author":"J Zhong","year":"2025","unstructured":"Zhong J, Peng Y, Zhang L, Xiao B, Zhang M (2025) Astrocyte lipid droplet dynamics orchestrate neurological disorders and therapeutic horizons. Small Science 5:2500152. https:\/\/doi.org\/10.1002\/SMSC.202500152","journal-title":"Small Science"},{"key":"6101_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/IJMM.2025.5691\/HTML","volume":"57","author":"Y Wang","year":"2026","unstructured":"Wang Y, Wang B, Hou J, Huo X, Liu C, Guan R, Chen H, Zhou Y, et al. (2026) Lipid droplets in astrocytes: key organelles for CNS homeostasis and disease (review). Int J Mol Med 57:1\u201317. https:\/\/doi.org\/10.3892\/IJMM.2025.5691\/HTML","journal-title":"Int J Mol Med"},{"issue":"19","key":"6101_CR82","doi-asserted-by":"publisher","DOI":"10.1101\/2025.08.19.669163","volume":"08","author":"C Cun\u00ed-L\u00f3pez","year":"2025","unstructured":"Cun\u00ed-L\u00f3pez C, Root JT, Hao Y, Kowal I, Blomberg N, Ghirlando R, Yang LG, Hertog SJK, Cookson MR, van der Kant R, Giera M, Qi YA, Narayan PS (2025) APOE genotypes differentially remodel the astrocytic lipid droplet-associated proteome to shape lipid droplet dynamics. BioRxiv 08(19):669163. https:\/\/doi.org\/10.1101\/2025.08.19.669163","journal-title":"BioRxiv"},{"key":"6101_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41514-025-00295-0","author":"S Sung","year":"2025","unstructured":"Sung S, Kim H-J, Cha SJ, Nahm M, Kim SH, Kwon M-S (2025) Microglial lipid droplets as therapeutic targets in age-related neurodegenerative diseases. Npj Aging. https:\/\/doi.org\/10.1038\/s41514-025-00295-0","journal-title":"Npj Aging"},{"key":"6101_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEUBIOREV.2024.105867","volume":"165","author":"Y Kang","year":"2024","unstructured":"Kang Y, Yeap YJ, Yang J, Ma S, Lim KL, Zhang Q, Lu L, Zhang C (2024) Role of lipid droplets in neurodegenerative diseases: from pathogenesis to therapeutics. Neurosci Biobehav Rev 165:105867. https:\/\/doi.org\/10.1016\/J.NEUBIOREV.2024.105867","journal-title":"Neurosci Biobehav Rev"},{"key":"6101_CR85","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00401-017-1746-2","volume":"134","author":"F Loria","year":"2017","unstructured":"Loria F, Vargas JY, Bousset L, Syan S, Salles A, Melki R, Zurzolo C (2017) \u03b1-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading. Acta Neuropathol 134:789\u2013808. https:\/\/doi.org\/10.1007\/s00401-017-1746-2","journal-title":"Acta Neuropathol"},{"key":"6101_CR86","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40035-018-0143-7","volume":"8","author":"SZ Lu","year":"2019","unstructured":"Lu SZ, Guo YS, Liang PZ, Zhang SZ, Yin S, Yin YQ, Wang XM, Ding F, et al. (2019) Suppression of astrocytic autophagy by \u03b1b-crystallin contributes to \u03b1-synuclein inclusion formation. Transl Neurodegener 8:3. https:\/\/doi.org\/10.1186\/s40035-018-0143-7","journal-title":"Transl Neurodegener"},{"key":"6101_CR87","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.neurobiolaging.2015.01.015","volume":"36","author":"Y Liu","year":"2015","unstructured":"Liu Y, Zhou Q, Tang M, Fu N, Shao W, Zhang S, Yin Y, Zeng R, et al. (2015) Upregulation of alphaB-crystallin expression in the substantia nigra of patients with Parkinson\u2019s disease. Neurobiol Aging 36:1686\u20131691. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2015.01.015","journal-title":"Neurobiol Aging"},{"key":"6101_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101039","volume":"59","author":"JL Gollihue","year":"2020","unstructured":"Gollihue JL, Norris CM (2020) Astrocyte mitochondria: central players and potential therapeutic targets for neurodegenerative diseases and injury. Ageing Res Rev 59:101039. https:\/\/doi.org\/10.1016\/j.arr.2020.101039","journal-title":"Ageing Res Rev"},{"key":"6101_CR89","doi-asserted-by":"publisher","first-page":"11835","DOI":"10.1523\/JNEUROSCI.0983-17.2017","volume":"37","author":"J Rostami","year":"2017","unstructured":"Rostami J, Holmqvist S, Lindstr\u00f6m V, Sigvardson J, Westermark GT, Ingelsson M, Bergstr\u00f6m J, Roybon L, et al. (2017) Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes. J Neurosci 37:11835\u201311853. https:\/\/doi.org\/10.1523\/JNEUROSCI.0983-17.2017","journal-title":"J Neurosci"},{"key":"6101_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-1018-z","volume":"14","author":"G Gustafsson","year":"2017","unstructured":"Gustafsson G, Lindstr\u00f6m V, Rostami J, Nordstr\u00f6m E, Lannfelt L, Bergstr\u00f6m J, Ingelsson M, Erlandsson A (2017) Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes. J Neuroinflammation 14:241. https:\/\/doi.org\/10.1186\/s12974-017-1018-z","journal-title":"J Neuroinflammation"},{"key":"6101_CR91","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.mito.2018.12.002","volume":"47","author":"KZ Kuter","year":"2019","unstructured":"Kuter KZ, Olech \u0141, Dencher NA (2019) Increased energetic demand supported by mitochondrial electron transfer chain and astrocyte assistance is essential to maintain the compensatory ability of the dopaminergic neurons in an animal model of early Parkinson\u2019s disease. Mitochondrion 47:227\u2013237. https:\/\/doi.org\/10.1016\/j.mito.2018.12.002","journal-title":"Mitochondrion"},{"key":"6101_CR92","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.bbi.2019.07.009","volume":"81","author":"ZL Hu","year":"2019","unstructured":"Hu ZL, Sun T, Lu M, Ding JH, Du RH, Hu G (2019) Kir6.1\/K-ATP channel on astrocytes protects against dopaminergic neurodegeneration in the MPTP mouse model of Parkinson\u2019s disease via promoting mitophagy. Brain Behav Immun 81:509\u2013522. https:\/\/doi.org\/10.1016\/j.bbi.2019.07.009","journal-title":"Brain Behav Immun"},{"key":"6101_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101284","volume":"23","author":"T Liang","year":"2020","unstructured":"Liang T, Qian ZM, Mu MD, Yung WH, Ke Y (2020) Brain hepcidin suppresses major pathologies in experimental parkinsonism. iScience 23:101284. https:\/\/doi.org\/10.1016\/j.isci.2020.101284","journal-title":"iScience"},{"key":"6101_CR94","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fnmol.2017.00455","volume":"10","author":"H Xu","year":"2018","unstructured":"Xu H, Wang Y, Song N, Wang J, Jiang H, Xie J (2018) New progress on the role of glia in iron metabolism and iron-induced degeneration of dopamine neurons in Parkinson\u2019s disease. Front Mol Neurosci 10:455. https:\/\/doi.org\/10.3389\/fnmol.2017.00455","journal-title":"Front Mol Neurosci"},{"key":"6101_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELREP.2025.116001","volume":"44","author":"MT Jeon","year":"2025","unstructured":"Jeon MT, Cogill SA, Kim KS, Kim Y, Kim H, Lee CY, Kim S, Son S, et al. (2025) TNF-\u03b1-NF-\u03baB activation through pathological \u03b1-synuclein disrupts the BBB and exacerbates axonopathy. Cell Rep 44:116001. https:\/\/doi.org\/10.1016\/J.CELREP.2025.116001","journal-title":"Cell Rep"},{"key":"6101_CR96","doi-asserted-by":"publisher","unstructured":"D\u2019Sa K, Choi ML, Wagen AZ, Set\u00f3-Salvia N, Kopach O, Evans JR, Rodrigues M, Lopez-Garcia P, Lachica J, Clarke BE, Singh J, Ghareeb A, Bayne J, Grant-Peters M, Garcia-Ruiz S, Chen Z, Rodriques S, Athauda D, Gustavsson EK, Gagliano Taliun SA, Toomey C, Reynolds RH, Young G, Strohbuecker S, Warner T, Rusakov DA, Patani R, Bryant C, Klenerman DA, Gandhi S, Ryten M (2025) Astrocytic RNA editing regulates the host immune response to alpha-synuclein. Science Advances 11. https:\/\/doi.org\/10.1126\/SCIADV.ADP8504;WEBSITE:WEBSITE:AAAS-SITE;REQUESTEDJOURNAL:JOURNAL:SCIADV;WGROUP:STRING:PUBLICATION","DOI":"10.1126\/SCIADV.ADP8504;WEBSITE:WEBSITE:AAAS-SITE;REQUESTEDJOURNAL:JOURNAL:SCIADV;WGROUP:STRING:PUBLICATION"},{"key":"6101_CR97","doi-asserted-by":"publisher","unstructured":"Bellucci A, Bubacco L, Longhena F, Parrella E, Faustini G, Porrini V, Bono F, Missale C, et al. (2020) Nuclear factor-\u03baB dysregulation and \u03b1-synuclein pathology: critical interplay in the pathogenesis of Parkinson\u2019s disease. Front Aging Neurosci 12:521268. https:\/\/doi.org\/10.3389\/FNAGI.2020.00068\/FULL","DOI":"10.3389\/FNAGI.2020.00068\/FULL"},{"key":"6101_CR98","doi-asserted-by":"publisher","unstructured":"Wang C, Yang T, Liang M, Xie J, Song N (2021) Astrocyte dysfunction in Parkinson\u2019s disease: from the perspectives of transmitted \u03b1-synuclein and genetic modulation. Transl Neurodegener 10:39. https:\/\/doi.org\/10.1186\/S40035-021-00265-","DOI":"10.1186\/S40035-021-00265-"},{"key":"6101_CR99","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/649079","volume":"2012","author":"SAL Corr\u00eaa","year":"2012","unstructured":"Corr\u00eaa SAL, Eales KL (2012) The role of p38 MAPK and its substrates in neuronal plasticity and neurodegenerative disease. J Signal Transduct 649079. https:\/\/doi.org\/10.1155\/2012\/649079","journal-title":"J Signal Transduct"},{"key":"6101_CR100","doi-asserted-by":"publisher","unstructured":"Lindstr\u00f6m V, Gustafsson G, Sanders LH, Howlett EH, Sigvardson J, Kasrayan A, Ingelsson M, Bergstr\u00f6m J, et al. (2017) Extensive uptake of \u03b1-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage. Mol Cell Neurosci 82:143\u2013156. https:\/\/doi.org\/10.1016\/J.MCN.2017.04.009","DOI":"10.1016\/J.MCN.2017.04.009"},{"key":"6101_CR101","unstructured":"Jha SK., Jha NK., Kar R, Ambasta RK, Kumar\u00a0 P (2015) MAPK and PI3K\/AKT signalling cascades inParkinson\u2019s disease, Int. J. Mol. Cell. Med. 4:67 p38. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4499569\/. Accessed 11 November 2025"},{"key":"6101_CR102","doi-asserted-by":"publisher","unstructured":"Gloeckner CJ, Schumacher A, Boldt K, Ueffing M (2009) The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3\/6 and MKK4\/7, in vitro. J Neurochem 109:959\u2013968. https:\/\/doi.org\/10.1111\/J.1471-4159.2009.06024.X;SUBPAGE:STRING:FULL","DOI":"10.1111\/J.1471-4159.2009.06024.X;SUBPAGE:STRING:FULL"},{"key":"6101_CR103","doi-asserted-by":"publisher","unstructured":"Yokoya M, Takata F, Iwao T, Matsumoto J, Tanaka Y, Aridome H, Yasunaga M, Mizoguchi J, Sano K, Dohgu S (2025) \u03b1-Synuclein degradation in brain pericytes is mediated via Akt, ERK, and p38 MAPK signaling pathways, International Journal of Molecular Sciences, Vol. 26, Page 1615. https:\/\/doi.org\/10.3390\/IJMS26041615","DOI":"10.3390\/IJMS26041615"},{"key":"6101_CR104","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1111\/J.1471-4159.2009.06112.X","volume":"109","author":"S Karunakaran","year":"2009","unstructured":"Karunakaran S, Ravindranath V (2009) Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF-\u03baB in MPTP-treated mice: implication in Parkinson\u2019s disease. J Neurochem 109:1791\u20131799. https:\/\/doi.org\/10.1111\/J.1471-4159.2009.06112.X","journal-title":"J Neurochem"},{"key":"6101_CR105","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/J.JPHS.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino L, Tremblay ME, Civiero L (2020) Glutamate-induced excitotoxicity in Parkinson\u2019s disease: the role of glial cells. J Pharmacol Sci 144:151\u2013164. https:\/\/doi.org\/10.1016\/J.JPHS.2020.07.011","journal-title":"J Pharmacol Sci"},{"issue":"5","key":"6101_CR106","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41580-020-00322-w","volume":"22","author":"B Canovas","year":"2021","unstructured":"Canovas B, Nebreda AR (2021) Diversity and versatility of p38 kinase signalling in health and disease. Nature Reviews Molecular Cell Biology 22(5):346\u2013366. https:\/\/doi.org\/10.1038\/s41580-020-00322-w","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"6101_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S00018-024-05419-5","volume":"81","author":"L Dai","year":"2024","unstructured":"Dai L, Liu M, Ke W, Chen L, Fang X, Zhang Z (2024) Lysosomal dysfunction in \u03b1-synuclein pathology: molecular mechanisms and therapeutic strategies. Cellular and Molecular Life Sciences 81:1\u201319. https:\/\/doi.org\/10.1007\/S00018-024-05419-5","journal-title":"Cellular and Molecular Life Sciences"},{"key":"6101_CR108","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/J.BBADIS.2013.12.011","volume":"1842","author":"L Gan","year":"2014","unstructured":"Gan L, Johnson JA (2014) Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases. Biochim Biophys Acta 1842:1208\u20131218. https:\/\/doi.org\/10.1016\/J.BBADIS.2013.12.011","journal-title":"Biochim Biophys Acta"},{"key":"6101_CR109","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/S00018-016-2223-0","volume":"73","author":"A Loboda","year":"2016","unstructured":"Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J (2016) Role of Nrf2\/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cell Mol Life Sci 73:3221. https:\/\/doi.org\/10.1007\/S00018-016-2223-0","journal-title":"Cell Mol Life Sci"},{"key":"6101_CR110","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.3390\/ANTIOX12111999\/S1","volume":"12","author":"JE Park","year":"2023","unstructured":"Park JE, Leem YH, Park JS, Kim SE, Kim HS (2023) Astrocytic Nrf2 mediates the neuroprotective and anti-inflammatory effects of nootkatone in an MPTP-induced Parkinson\u2019s disease mouse model. Antioxidants 12:1999. https:\/\/doi.org\/10.3390\/ANTIOX12111999\/S1","journal-title":"Antioxidants"},{"key":"6101_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/S40035-024-00401-4","volume":"13","author":"E Leandrou","year":"2024","unstructured":"Leandrou E, Chalatsa I, Anagnostou D, Machalia C, Semitekolou M, Filippa V, Makridakis M, Vlahou A, et al. (2024) \u03b1-Synuclein oligomers potentiate neuroinflammatory NF-\u03baB activity and induce Cav3.2 calcium signaling in astrocytes. Transl Neurodegener 13:11. https:\/\/doi.org\/10.1186\/S40035-024-00401-4","journal-title":"Transl Neurodegener"},{"key":"6101_CR112","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/IJMS26020687\/S1","volume":"26","author":"J He","year":"2025","unstructured":"He J, Hewett SJ (2025) Nrf2 regulates basal glutathione production in astrocytes. Int J Mol Sci 26:687. https:\/\/doi.org\/10.3390\/IJMS26020687\/S1","journal-title":"Int J Mol Sci"},{"key":"6101_CR113","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/NEUROSCI5010005","volume":"5","author":"D Brash-Arias","year":"2024","unstructured":"Brash-Arias D, Garc\u00eda LI, P\u00e9rez-Estudillo CA, Rojas-Dur\u00e1n F, Aranda-Abreu GE, Herrera-Covarrubias D, Chi-Casta\u00f1eda D (2024) The role of astrocytes and alpha-synuclein in Parkinson\u2019s disease: a review. NeuroSci 5:71\u201386. https:\/\/doi.org\/10.3390\/NEUROSCI5010005","journal-title":"NeuroSci"},{"key":"6101_CR114","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.129719","volume":"4","author":"ML Arotcarena","year":"2019","unstructured":"Arotcarena ML, Bourdenx M, Dutheil N, Thiolat ML, Doudnikoff E, Dovero S, Ballabio A, Fernagut PO, et al. (2019) Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies. JCI Insight 4:e129719. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.129719","journal-title":"JCI Insight"},{"key":"6101_CR115","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/MDS.27895","volume":"35","author":"G Bellomo","year":"2020","unstructured":"Bellomo G, Paciotti S, Gatticchi L, Parnetti L (2020) The vicious cycle between \u03b1-synuclein aggregation and autophagic-lysosomal dysfunction. Mov Disord 35:34\u201344. https:\/\/doi.org\/10.1002\/MDS.27895","journal-title":"Mov Disord"},{"key":"6101_CR116","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/BS.MCB.2014.11.011","volume":"126","author":"C Settembre","year":"2015","unstructured":"Settembre C, Medina DL (2015) TFEB and the CLEAR network. Methods Cell Biol 126:45\u201362. https:\/\/doi.org\/10.1016\/BS.MCB.2014.11.011","journal-title":"Methods Cell Biol"},{"key":"6101_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0120819","volume":"10","author":"K Kilpatrick","year":"2015","unstructured":"Kilpatrick K, Zeng Y, Hancock T, Segatori L (2015) Genetic and chemical activation of TFEB mediates clearance of aggregated \u03b1-synuclein. PLoS ONE 10:e0120819. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0120819","journal-title":"PLoS ONE"},{"key":"6101_CR118","doi-asserted-by":"publisher","first-page":"E1817","DOI":"10.1073\/PNAS.1305623110\/-\/DCSUPPLEMENTAL","volume":"110","author":"M Decressac","year":"2013","unstructured":"Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Bj\u00f6rklund A (2013) TFEB-mediated autophagy rescues midbrain dopamine neurons from \u03b1-synuclein toxicity. Proc Natl Acad Sci U S A 110:E1817. https:\/\/doi.org\/10.1073\/PNAS.1305623110\/-\/DCSUPPLEMENTAL","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6101_CR119","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41531-021-00175-w","volume":"7","author":"P Ramos-Gonzalez","year":"2021","unstructured":"Ramos-Gonzalez P, Mato S, Chara JC, Verkhratsky A, Matute C, Cavaliere F (2021) Astrocytic atrophy as a pathological feature of Parkinson\u2019s disease with LRRK2 mutation. Npj Parkinson\u2019s Disease 7(1):71\u201311. https:\/\/doi.org\/10.1038\/s41531-021-00175-w","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"6101_CR120","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1007\/S12035-021-02327-8","volume":"58","author":"L Streubel-Gallasch","year":"2021","unstructured":"Streubel-Gallasch L, Giusti V, Sandre M, Tessari I, Plotegher N, Giusto E, Masato A, Iovino L, et al. (2021) Parkinson\u2019s disease\u2013associated LRRK2 interferes with astrocyte-mediated alpha-synuclein clearance. Mol Neurobiol 58:3119. https:\/\/doi.org\/10.1007\/S12035-021-02327-8","journal-title":"Mol Neurobiol"},{"key":"6101_CR121","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3233\/JPD-230284\/ASSET\/7983C896-A134-45BF-B0D9-0E1FADF89BB1\/ASSETS\/GRAPHIC\/10.3233_JPD-230284-FIG2.JPG","volume":"13","author":"H Ozoran","year":"2023","unstructured":"Ozoran H, Srinivasan R (2023) Astrocytes and alpha-synuclein: friend or foe? J Parkinsons Dis 13:1289\u20131301. https:\/\/doi.org\/10.3233\/JPD-230284\/ASSET\/7983C896-A134-45BF-B0D9-0E1FADF89BB1\/ASSETS\/GRAPHIC\/10.3233_JPD-230284-FIG2.JPG","journal-title":"J Parkinsons Dis"},{"key":"6101_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105080","volume":"148","author":"YY Fan","year":"2021","unstructured":"Fan YY, Huo J (2021) A1\/A2 astrocytes in central nervous system injuries and diseases: angels or devils? Neurochem Int 148:105080. https:\/\/doi.org\/10.1016\/j.neuint.2021.105080","journal-title":"Neurochem Int"},{"key":"6101_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.703810","volume":"15","author":"AJ Moulson","year":"2021","unstructured":"Moulson AJ, Squair JW, Franklin RJM, Tetzlaff W, Assinck P (2021) Diversity of reactive astrogliosis in CNS pathology: heterogeneity or plasticity? Front Cell Neurosci 15:703810. https:\/\/doi.org\/10.3389\/fncel.2021.703810","journal-title":"Front Cell Neurosci"},{"key":"6101_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/J.NBD.2020.105028","volume":"144","author":"TI Kam","year":"2020","unstructured":"Kam TI, Hinkle JT, Dawson TM, Dawson VL (2020) Microglia and astrocyte dysfunction in Parkinson\u2019s disease. Neurobiol Dis 144:105028. https:\/\/doi.org\/10.1016\/J.NBD.2020.105028","journal-title":"Neurobiol Dis"},{"key":"6101_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/S41531-025-00995-0","author":"S Zhang","year":"2025","unstructured":"Zhang S, Yan M, Jiang X, Liu Y, Ma W, Ding L, Lu Z, Luo Y, et al. (2025) Oligodendrocyte-astrocyte crosstalk in Parkinson\u2019s disease mediates neuronal ferroptosis via the FGF signaling pathway. NPJ Park Dis. https:\/\/doi.org\/10.1038\/S41531-025-00995-0","journal-title":"NPJ Park Dis"},{"key":"6101_CR126","doi-asserted-by":"publisher","DOI":"10.7717\/PEERJ.19998","volume":"13","author":"Z Li","year":"2025","unstructured":"Li Z, Cao M, Yin Z, Li X, Wang Q, Dong P, Zhou C (2025) Functional characteristics, intercellular interactions and pathophysiological associations of astrocytes in Parkinson\u2019s disease. PeerJ 13:e19998. https:\/\/doi.org\/10.7717\/PEERJ.19998","journal-title":"PeerJ"},{"key":"6101_CR127","doi-asserted-by":"publisher","DOI":"10.1101\/2023.03.12.532248","author":"Z Tang","year":"2023","unstructured":"Tang Z, Chen Z, Min G, Peng Y, Xiao Y, Guan Z, Ni R, Qi X (2023) NRF2 deficiency promotes ferroptosis of astrocytes mediated by oxidative stress in Alzheimer\u2019s disease. BioRxiv. https:\/\/doi.org\/10.1101\/2023.03.12.532248","journal-title":"BioRxiv"},{"key":"6101_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/FNINS.2020.00267","volume":"14","author":"X Song","year":"2020","unstructured":"Song X, Long D (2020) Nrf2 and ferroptosis: a new research direction for neurodegenerative diseases. Front Neurosci 14:267. https:\/\/doi.org\/10.3389\/FNINS.2020.00267","journal-title":"Front Neurosci"},{"key":"6101_CR129","doi-asserted-by":"publisher","unstructured":"Ali A, Babar Q, Saeed A, Sergi D, Naumovski N, Mohamed Ahmed IA, Shamlan G, Hafiz HA, Manzoor MF, Trafialek J, Madilo FK (2025) Emerging links between ferroptosis and neurodegeneration: implications for disease mechanisms and nutraceutical interventions. Food Sci. Nutr. 13. https:\/\/doi.org\/10.1002\/FSN3.70385;WGROUP:STRING:PUBLICATION","DOI":"10.1002\/FSN3.70385;WGROUP:STRING:PUBLICATION"},{"key":"6101_CR130","doi-asserted-by":"publisher","unstructured":"A. Mamais, R.D. Batchelor, A. Chairmandurai, N. Subrahmanian, N. Maio, C.D. Vulpe, M.J. LaVoie, Parkinson\u2019s disease LRRK2 mutations dysregulate iron homeostasis and promote oxidative stress and ferroptosis in human neurons and astrocytes, BioRxiv (2025) 2025.09.26.678370. https:\/\/doi.org\/10.1101\/2025.09.26.678370.","DOI":"10.1101\/2025.09.26.678370"},{"key":"6101_CR131","doi-asserted-by":"publisher","first-page":"1510897","DOI":"10.3389\/FCELL.2024.1510897\/FULL","volume":"12","author":"M Li","year":"2024","unstructured":"Li M, Chen M, Li H, Gao D, Zhao L, Zhu M (2024) Glial cells improve Parkinson\u2019s disease by modulating neuronal function and regulating neuronal ferroptosis. Front Cell Dev Biol 12:1510897. https:\/\/doi.org\/10.3389\/FCELL.2024.1510897\/FULL","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"6101_CR132","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41531-025-00995-0","volume":"11","author":"S Zhang","year":"2025","unstructured":"Zhang S, Yan M, Jiang X, Liu Y, Ma W, Ding L, Lu Z, Luo Y, Tian X, Wang Q (2025) Oligodendrocyte-astrocyte crosstalk in Parkinson\u2019s disease mediates neuronal ferroptosis via the FGF signaling pathway. Npj Parkinson\u2019s Disease 11(1):136. https:\/\/doi.org\/10.1038\/s41531-025-00995-0","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"6101_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/IJMM.2025.5526\/ABSTRACT","volume":"55","author":"H Zhi","year":"2025","unstructured":"Zhi H, Wang X, Chen Y, Cai Z, Li J, Guo D (2025) Ceftriaxone affects ferroptosis and alleviates glial cell activation in Parkinson\u2019s disease. Int J Mol Med 55:1\u201314. https:\/\/doi.org\/10.3892\/IJMM.2025.5526\/ABSTRACT","journal-title":"Int J Mol Med"},{"key":"6101_CR134","doi-asserted-by":"publisher","unstructured":"Keener AM, Bordelon YM (2016) Parkinsonism. Semin Neurol 36:330\u2013334. https:\/\/doi.org\/10.1055\/s-0036-1585097","DOI":"10.1055\/s-0036-1585097"},{"key":"6101_CR135","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2174\/0118715273270473231002104610","volume":"23","author":"B Bhushan","year":"2024","unstructured":"Bhushan B, Singh NK (2024) Role of astrogliosis in the pathogenesis of Parkinson\u2019s disease: insights into astrocytic Nrf2 pathway as a potential therapeutic target. CNS Neurol Disord Drug Targets 23:1015\u20131029. https:\/\/doi.org\/10.2174\/0118715273270473231002104610","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"6101_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0309893","volume":"19","author":"A Minnella","year":"2024","unstructured":"Minnella A, McCusker KP, Amagata A, Trias B, Weetall M, Latham JC, O\u2019Neill S, Wyse RK, et al. (2024) Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson\u2019s disease. PLoS One 19:e0309893. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0309893","journal-title":"PLoS One"},{"key":"6101_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/J.ARR.2019.100942","volume":"54","author":"L F\u00e3o","year":"2019","unstructured":"F\u00e3o L, Mota SI, Rego AC (2019) Shaping the Nrf2-ARE-related pathways in Alzheimer\u2019s and Parkinson\u2019s diseases. Ageing Res Rev 54:100942. https:\/\/doi.org\/10.1016\/J.ARR.2019.100942","journal-title":"Ageing Res Rev"},{"key":"6101_CR138","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/S12035-014-8845-Z","volume":"52","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Zhang X, Qu S (2015) Ceftriaxone protects astrocytes from MPP(+) via suppression of NF-\u03baB\/JNK\/c-Jun signaling. Mol Neurobiol 52:78\u201392. https:\/\/doi.org\/10.1007\/S12035-014-8845-Z","journal-title":"Mol Neurobiol"},{"key":"6101_CR139","doi-asserted-by":"publisher","DOI":"10.3892\/IJMM.2025.5526","author":"H Zhi","year":"2025","unstructured":"Zhi H, Wang X, Chen Y, Cai Z, Li J, Guo D (2025) Ceftriaxone affects ferroptosis and alleviates glial cell activation in Parkinson\u2019s disease. Int J Mol Med. https:\/\/doi.org\/10.3892\/IJMM.2025.5526","journal-title":"Int J Mol Med"},{"key":"6101_CR140","doi-asserted-by":"publisher","unstructured":"Bento-Pereira C, Dinkova-Kostova AT (2021) Activation of transcription factor Nrf2 to counteract mitochondrial dysfunction in Parkinson\u2019s disease. Med Res Rev 41:785\u2013802. https:\/\/doi.org\/10.1002\/MED.21714;ISSUE:ISSUE:DOI","DOI":"10.1002\/MED.21714;ISSUE:ISSUE:DOI"},{"key":"6101_CR141","doi-asserted-by":"publisher","first-page":"1659216","DOI":"10.3389\/FNAGI.2025.1659216\/FULL","volume":"17","author":"H Zhang","year":"2025","unstructured":"Zhang H, He Z, Yin C, Yang S, Li J, Lin H, Hu G, Wu A, et al. (2025) STING-mediated neuroinflammation: a therapeutic target in neurodegenerative diseases. Front Aging Neurosci 17:1659216. https:\/\/doi.org\/10.3389\/FNAGI.2025.1659216\/FULL","journal-title":"Front Aging Neurosci"},{"key":"6101_CR142","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, et al. (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 23:37\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(23)00378-2","journal-title":"Lancet Neurol"},{"key":"6101_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELREP.2020.108271","volume":"33","author":"JK Sterling","year":"2020","unstructured":"Sterling JK, Adetunji MO, Guttha S, Bargoud AR, Uyhazi KE, Ross AG, Dunaief JL, Cui QN (2020) GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension. Cell Rep 33:108271. https:\/\/doi.org\/10.1016\/J.CELREP.2020.108271","journal-title":"Cell Rep"},{"key":"6101_CR144","unstructured":"Study Details | NCT02953665 | Safety and efficacy of liraglutide in Parkinson\u2019s disease | ClinicalTrials.gov, (n.d.). \nhttps:\/\/clinicaltrials.gov\/study\/NCT02953665. Accessed 10  April 2026"},{"key":"6101_CR145","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, et al. (2017) Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664\u20131675. https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4","journal-title":"Lancet"},{"key":"6101_CR146","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/JAMANEUROL.2018.4304","volume":"76","author":"D Athauda","year":"2019","unstructured":"Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, Chawla S, Chowdhury K, et al. (2019) Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial. JAMA Neurol 76:420\u2013429. https:\/\/doi.org\/10.1001\/JAMANEUROL.2018.4304","journal-title":"JAMA Neurol"},{"key":"6101_CR147","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000041218","volume":"104","author":"D Jiao","year":"2025","unstructured":"Jiao D, Yang Y, Wang K, Wang Y (2025) Ferroptosis: a novel pathogenesis and therapeutic strategies for Parkinson disease: a review. Medicine 104:e41218. https:\/\/doi.org\/10.1097\/MD.0000000000041218","journal-title":"Medicine"},{"key":"6101_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/J.ARR.2023.102077","volume":"91","author":"X shen Ding","year":"2023","unstructured":"shen Ding X, Gao L, Han Z, Eleuteri S, Shen Y, yao Song Z, Su M, Yang Q, Qu Y, Simon DK, lian Wang X, Wang B (2023) Ferroptosis in Parkinson\u2019s disease: molecular mechanisms and therapeutic potential. Ageing Res. Rev. 91:102077. https:\/\/doi.org\/10.1016\/J.ARR.2023.102077","journal-title":"Ageing Res. Rev."},{"key":"6101_CR149","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/J.TIPS.2023.08.012","volume":"44","author":"C Scarpellini","year":"2023","unstructured":"Scarpellini C, Klejborowska G, Lanthier C, Hassannia B, Vanden Berghe T, Augustyns K (2023) Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors. Trends Pharmacol Sci 44:902\u2013916. https:\/\/doi.org\/10.1016\/J.TIPS.2023.08.012","journal-title":"Trends Pharmacol Sci"},{"key":"6101_CR150","doi-asserted-by":"publisher","unstructured":"Devos D, Labreuche J, Rascol O, Corvol J-C, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, et al. (2022) Trial of deferiprone in Parkinson\u2019s disease. N Engl J Med 387:2045\u20132055. https:\/\/doi.org\/10.1056\/NEJMOA2209254","DOI":"10.1056\/NEJMOA2209254"},{"key":"6101_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2026.116628","volume":"179","author":"AM Abdelaziz","year":"2026","unstructured":"Abdelaziz AM (2026) The cGAS-STING-glymphatic-gut axis in Parkinson\u2019s disease: a proposed self-amplifying triad of neuroinflammation and therapeutic opportunity. Int Immunopharmacol 179:116628. https:\/\/doi.org\/10.1016\/J.INTIMP.2026.116628","journal-title":"Int Immunopharmacol"},{"key":"6101_CR152","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/ars.2015.6549","volume":"25","author":"I Lastres-Becker","year":"2016","unstructured":"Lastres-Becker I, Garc\u00eda-Yag\u00fce AJ, Scannevin RH, Casarejos MJ, K\u00fcgler S, R\u00e1bano A, Cuadrado A (2016) Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson\u2019s disease. Antioxid Redox Signal 25:61. https:\/\/doi.org\/10.1089\/ars.2015.6549","journal-title":"Antioxid Redox Signal"},{"key":"6101_CR153","doi-asserted-by":"publisher","first-page":"1437939","DOI":"10.3389\/FPHAR.2024.1437939\/FULL","volume":"15","author":"C Mayer","year":"2024","unstructured":"Mayer C, Riera-Ponsati L, Kauppinen S, Klitgaard H, Erler JT, Hansen SN (2024) Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: mechanisms and therapeutic implications. Front Pharmacol 15:1437939. https:\/\/doi.org\/10.3389\/FPHAR.2024.1437939\/FULL","journal-title":"Front Pharmacol"},{"key":"6101_CR154","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, Hibbert S, Wong A, et al. (2025) Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet 405:627\u2013636. https:\/\/doi.org\/10.1016\/S0140-6736(24)02808-3","journal-title":"Lancet"},{"key":"6101_CR155","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.nurt.2010.07.001","volume":"7","author":"PM Rappold","year":"2010","unstructured":"Rappold PM, Tieu K (2010) Astrocytes and therapeutics for Parkinson\u2019s disease. Neurotherapeutics 7:413\u2013423. https:\/\/doi.org\/10.1016\/j.nurt.2010.07.001","journal-title":"Neurotherapeutics"},{"key":"6101_CR156","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks","year":"2010","unstructured":"Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, et al. (2010) Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9:1164\u20131172. https:\/\/doi.org\/10.1016\/S1474-4422(10)70254-4","journal-title":"Lancet Neurol"},{"key":"6101_CR157","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/brb3.117","volume":"3","author":"S Back","year":"2013","unstructured":"Back S, Per\u00e4nen J, Galli E, Pulkkila P, Lonka-Nevalaita L, Tamminen T, Voutilainen MH, Raasmaja A, et al. (2013) Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson\u2019s disease. Brain Behav 3:75\u201388. https:\/\/doi.org\/10.1002\/brb3.117","journal-title":"Brain Behav"},{"key":"6101_CR158","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, M\u00fcnch AE, et al. (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481\u2013487. https:\/\/doi.org\/10.1038\/nature21029","journal-title":"Nature"},{"key":"6101_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2016.159","volume":"49","author":"YC Chung","year":"2017","unstructured":"Chung YC, Baek JY, Kim SR, Ko HW, Bok E, Shin WH, Won SY, Jin BK (2017) Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson\u2019s disease. Exp Mol Med 49:e298. https:\/\/doi.org\/10.1038\/emm.2016.159","journal-title":"Exp Mol Med"},{"key":"6101_CR160","doi-asserted-by":"publisher","first-page":"5093493","DOI":"10.1155\/2020\/5093493","volume":"2020","author":"R Wi","year":"2020","unstructured":"Wi R, Chung YC, Jin BK (2020) Functional crosstalk between CB and TRPV1 receptors protects nigrostriatal dopaminergic neurons in the MPTP model of Parkinson\u2019s disease. J Immunol Res 2020:5093493. https:\/\/doi.org\/10.1155\/2020\/5093493","journal-title":"J Immunol Res"},{"key":"6101_CR161","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1007\/s11064-017-2388-4","volume":"42","author":"ZX Zhao","year":"2017","unstructured":"Zhao ZX, Wang JF, Wang LL, Yao XM, Liu YL, Li Y, Chen S, Yue T, et al. (2017) Capsaicin protects against oxidative insults and alleviates behavioral deficits in rats with 6-OHDA-induced Parkinson\u2019s disease via activation of TRPV1. Neurochem Res 42:3431\u20133438. https:\/\/doi.org\/10.1007\/s11064-017-2388-4","journal-title":"Neurochem Res"},{"key":"6101_CR162","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000513678","volume":"28","author":"RW Du","year":"2021","unstructured":"Du RW, Bu WG (2021) Simvastatin prevents neurodegeneration in the MPTP mouse model of Parkinson\u2019s disease via inhibition of A1 reactive astrocytes. NeuroImmunoModulation 28:82\u201389. https:\/\/doi.org\/10.1159\/000513678","journal-title":"NeuroImmunoModulation"},{"key":"6101_CR163","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fnmol.2018.00165","volume":"11","author":"H Tong","year":"2018","unstructured":"Tong H, Zhang X, Meng X, Lu L, Mai D, Qu S (2018) Simvastatin inhibits activation of NADPH oxidase\/p38 MAPK pathway and enhances expression of antioxidant protein in Parkinson disease models. Front Mol Neurosci 11:165. https:\/\/doi.org\/10.3389\/fnmol.2018.00165","journal-title":"Front Mol Neurosci"},{"key":"6101_CR164","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/glia.22974","volume":"64","author":"N Yamamoto","year":"2016","unstructured":"Yamamoto N, Fujii Y, Kasahara R, Tanida M, Ohora K, Ono Y, Suzuki K, Sobue K (2016) Simvastatin and atorvastatin facilitates amyloid \u03b2-protein degradation in extracellular spaces by increasing neprilysin secretion from astrocytes through activation of MAPK\/Erk1\/2 pathways. Glia 64:952\u2013962. https:\/\/doi.org\/10.1002\/glia.22974","journal-title":"Glia"},{"key":"6101_CR165","doi-asserted-by":"publisher","unstructured":"Wei ZYD, Shetty AK (2021) Treating Parkinson\u2019s disease by astrocyte reprogramming: progress and challenges. Sci. Adv. 7. https:\/\/doi.org\/10.1126\/sciadv.abg3198","DOI":"10.1126\/sciadv.abg3198"},{"key":"6101_CR166","doi-asserted-by":"publisher","unstructured":"Nam YR, Kang M, Kim M, Seok MJ, Yang Y, Han YE, Oh SJ, Kim DG, et al. (2024) Preparation of human astrocytes with potent therapeutic functions from human pluripotent stem cells using ventral midbrain patterning. J Adv Res. https:\/\/doi.org\/10.1016\/j.jare.2024.03.012","DOI":"10.1016\/j.jare.2024.03.012"},{"key":"6101_CR167","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s12031-008-9166-3","volume":"39","author":"M Bahat-Stroomza","year":"2009","unstructured":"Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S, Melamed E, Offen D (2009) Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson\u2019s disease. J Mol Neurosci 39:199\u2013210. https:\/\/doi.org\/10.1007\/s12031-008-9166-3","journal-title":"J Mol Neurosci"},{"key":"6101_CR168","doi-asserted-by":"publisher","unstructured":"Gan L, Vargas MR, Johnson DA, Johnson JA (2012) Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. J Neurosci 32:17775\u201317787. https:\/\/doi.org\/10.1523\/JNEUROSCI.3049-12.2012","DOI":"10.1523\/JNEUROSCI.3049-12.2012"},{"key":"6101_CR169","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/ANTIOX6030065","volume":"6","author":"JR Liddell","year":"2017","unstructured":"Liddell JR (2017) Are astrocytes the predominant cell type for activation of Nrf2 in aging and neurodegeneration? Antioxidants 6:65. https:\/\/doi.org\/10.3390\/ANTIOX6030065","journal-title":"Antioxidants"},{"key":"6101_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS9122623","volume":"9","author":"I Miyazaki","year":"2020","unstructured":"Miyazaki I, Asanuma M (2020) Neuron-astrocyte interactions in Parkinson\u2019s disease. Cells 9:2623. https:\/\/doi.org\/10.3390\/CELLS9122623","journal-title":"Cells"},{"key":"6101_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2023.109986","author":"RM El-Sayed","year":"2023","unstructured":"El-Sayed RM, Abdelaziz AM, Zaki HF, Abdel Rasheed NO (2023) Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson\u2019s disease in rats: correlation between Nrf2 and HMGB1\/TLR4\/PI3K\/Akt\/mTOR signaling. Int Immunopharmacol. https:\/\/doi.org\/10.1016\/J.INTIMP.2023.109986","journal-title":"Int Immunopharmacol"},{"key":"6101_CR172","doi-asserted-by":"publisher","unstructured":"Cui J, Guo X, Li Q, Song N, Xie J (2020) Hepcidin-to-ferritin ratio is decreased in astrocytes with extracellular alpha-synuclein and iron exposure. Front Cell Neurosci 14:523399. https:\/\/doi.org\/10.3389\/FNCEL.2020.00047\/BIBTEX","DOI":"10.3389\/FNCEL.2020.00047\/BIBTEX"},{"key":"6101_CR173","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/J.BBADIS.2018.01.008","volume":"1864","author":"N Song","year":"2018","unstructured":"Song N, Wang J, Jiang H, Xie J (2018) Astroglial and microglial contributions to iron metabolism disturbance in Parkinson\u2019s disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1864:967\u2013973. https:\/\/doi.org\/10.1016\/J.BBADIS.2018.01.008","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"6101_CR174","doi-asserted-by":"publisher","first-page":"8684130","DOI":"10.1155\/2016\/8684130","volume":"2016","author":"Q Xu","year":"2016","unstructured":"Xu Q, Kanthasamy AG, Jin H, Reddy MB (2016) Hepcidin plays a key role in 6-OHDA induced iron overload and apoptotic cell death in a cell culture model of Parkinson\u2019s disease. Parkinsons Dis 2016:8684130. https:\/\/doi.org\/10.1155\/2016\/8684130","journal-title":"Parkinsons Dis"},{"key":"6101_CR175","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1177\/1535370220953065","volume":"245","author":"SR D\u2019Mello","year":"2020","unstructured":"D\u2019Mello SR, Kindy MC (2020) Overdosing on iron: elevated iron and degenerative brain disorders. Exp Biol Med 245:1444. https:\/\/doi.org\/10.1177\/1535370220953065","journal-title":"Exp Biol Med"},{"key":"6101_CR176","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/J.NBD.2019.02.020","volume":"127","author":"KS Kirkley","year":"2019","unstructured":"Kirkley KS, Popichak KA, Hammond SL, Davies C, Hunt L, Tjalkens RB (2019) Genetic suppression of IKK2\/NF-\u03baB in astrocytes inhibits neuroinflammation and reduces neuronal loss in the MPTP-probenecid model of Parkinson\u2019s disease. Neurobiol Dis 127:193. https:\/\/doi.org\/10.1016\/J.NBD.2019.02.020","journal-title":"Neurobiol Dis"},{"key":"6101_CR177","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1007\/S00018-019-03111-7","volume":"76","author":"M Oksanen","year":"2019","unstructured":"Oksanen M, Lehtonen S, Jaronen M, Goldsteins G, H\u00e4m\u00e4l\u00e4inen RH, Koistinaho J (2019) Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms. Cell Mol Life Sci 76:2739. https:\/\/doi.org\/10.1007\/S00018-019-03111-7","journal-title":"Cell Mol Life Sci"},{"key":"6101_CR178","doi-asserted-by":"publisher","first-page":"18754","DOI":"10.1073\/PNAS.0704908104","volume":"104","author":"A Ghosh","year":"2007","unstructured":"Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, et al. (2007) Selective inhibition of NF-\u03baB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson\u2019s disease. Proc Natl Acad Sci U S A 104:18754. https:\/\/doi.org\/10.1073\/PNAS.0704908104","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6101_CR179","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/J.NEUROBIOLAGING.2015.03.015","volume":"36","author":"T Jiang","year":"2015","unstructured":"Jiang T, Hoekstra J, Heng X, Kang W, Ding J, Liu J, Chen S, Zhang J (2015) P2X7 receptor is critical in \u03b1-synuclein-mediated microglial NADPH oxidase activation. Neurobiol Aging 36:2304\u20132318. https:\/\/doi.org\/10.1016\/J.NEUROBIOLAGING.2015.03.015","journal-title":"Neurobiol Aging"},{"key":"6101_CR180","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/IMM.13264","volume":"162","author":"F Baidya","year":"2021","unstructured":"Baidya F, Bohra M, Datta A, Sarmah D, Shah B, Jagtap P, Raut S, Sarkar A, et al. (2021) Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases. Immunology 162:160\u2013178. https:\/\/doi.org\/10.1111\/IMM.13264","journal-title":"Immunology"},{"key":"6101_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71329-8","volume":"10","author":"TM Sonninen","year":"2020","unstructured":"Sonninen TM, H\u00e4m\u00e4l\u00e4inen RH, Koskuvi M, Oksanen M, Shakirzyanova A, Wojciechowski S, Puttonen K, Naumenko N, Goldsteins G, Laham-Karam N, Lehtonen M, Tavi P, Koistinaho J, Lehtonen \u0160 (2020) Metabolic alterations in Parkinson\u2019s disease astrocytes. Scientific Reports 10:114474. https:\/\/doi.org\/10.1038\/s41598-020-71329-8","journal-title":"Scientific Reports"},{"key":"6101_CR182","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, et al. (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol 125:795\u2013813. https:\/\/doi.org\/10.1007\/s00401-013-1114-9","journal-title":"Acta Neuropathol"},{"key":"6101_CR183","doi-asserted-by":"publisher","DOI":"10.1111\/TRA.12951","volume":"25","author":"H Liu","year":"2024","unstructured":"Liu H, Mao H, Ouyang X, Lu R, Li L (2024) Intercellular mitochondrial transfer: the novel therapeutic mechanism for diseases. Traffic 25:e12951. https:\/\/doi.org\/10.1111\/TRA.12951","journal-title":"Traffic"},{"key":"6101_CR184","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2023.114268","volume":"159","author":"R Jain","year":"2023","unstructured":"Jain R, Begum N, Tryphena KP, Singh SB, Srivastava S, Rai SN, Vamanu E, Khatri DK (2023) Inter and intracellular mitochondrial transfer: future of mitochondrial transplant therapy in Parkinson\u2019s disease. Biomed Pharmacother 159:114268. https:\/\/doi.org\/10.1016\/J.BIOPHA.2023.114268","journal-title":"Biomed Pharmacother"},{"key":"6101_CR185","doi-asserted-by":"publisher","DOI":"10.1111\/EJN.70463","volume":"63","author":"A Henrich","year":"2026","unstructured":"Henrich A, Scheiblich H (2026) Mobile powerhouses: mitochondria transfer via tunnelling nanotubes in brain health and neurodegenerative diseases. Eur J Neurosci 63:e70463. https:\/\/doi.org\/10.1111\/EJN.70463","journal-title":"Eur J Neurosci"},{"key":"6101_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/J.REDOX.2026.104019","volume":"90","author":"J Wang","year":"2026","unstructured":"Wang J, Li R, Qian L (2026) Intercellular mitochondrial transfer rewires redox signaling and metabolic plasticity: mechanisms, disease relevance and therapeutic frontiers. Redox Biol 90:104019. https:\/\/doi.org\/10.1016\/J.REDOX.2026.104019","journal-title":"Redox Biol"},{"key":"6101_CR187","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/J.NEUROSCIENCE.2021.11.035","volume":"481","author":"K Yamagata","year":"2022","unstructured":"Yamagata K (2022) Lactate supply from astrocytes to neurons and its role in ischemic stroke-induced neurodegeneration. Neuroscience 481:219\u2013231. https:\/\/doi.org\/10.1016\/J.NEUROSCIENCE.2021.11.035","journal-title":"Neuroscience"},{"key":"6101_CR188","doi-asserted-by":"publisher","unstructured":"de Rus Jacquet A, Alpaugh M, Denis HL, Tancredi JL, Boutin M, Decaestecker J, Beauparlant C, Herrmann L, Saint-Pierre M, Parent M, Droit A, Breton S, Cicchetti F (2023) The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson\u2019s disease. Nature Communications 141\u201321. https:\/\/doi.org\/10.1038\/s41467-023-39038-8","DOI":"10.1038\/s41467-023-39038-8"},{"key":"6101_CR189","doi-asserted-by":"publisher","unstructured":"Argaw AT, Asp L, Zhang J, Navrazhina K, Pham T, Mariani JN, Mahase S, Dutta DJ, et al. (2012) Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 122:2454\u20132468. https:\/\/doi.org\/10.1172\/JCI60842","DOI":"10.1172\/JCI60842"},{"key":"6101_CR190","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS242417146","volume":"24","author":"DR Manu","year":"2023","unstructured":"Manu DR, Slevin M, Barcutean L, Forro T, Boghitoiu T, Balasa R (2023) Astrocyte involvement in blood\u2013brain barrier function: a critical update highlighting novel, complex, neurovascular interactions. Int J Mol Sci 24:17146. https:\/\/doi.org\/10.3390\/IJMS242417146","journal-title":"Int J Mol Sci"},{"key":"6101_CR191","doi-asserted-by":"publisher","first-page":"1765195","DOI":"10.3389\/FNAGI.2026.1765195\/FULL","volume":"18","author":"AC Stoll","year":"2026","unstructured":"Stoll AC, Harms AS (2026) Interconnected roles of astrocytes and the blood\u2013brain barrier in Parkinson\u2019s disease: pathological evidence, mechanistic insights, and knowledge gaps. Front Aging Neurosci 18:1765195. https:\/\/doi.org\/10.3389\/FNAGI.2026.1765195\/FULL","journal-title":"Front Aging Neurosci"},{"key":"6101_CR192","doi-asserted-by":"publisher","unstructured":"Zhang Y, Tan F, Xu P, Qu S (2016) Recent advance in the relationship between excitatory amino acid transporters and Parkinson\u2019s disease. Neural Plast 2016:8941327. https:\/\/doi.org\/10.1155\/2016\/8941327","DOI":"10.1155\/2016\/8941327"},{"key":"6101_CR193","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/CELLS8020184","volume":"8","author":"S Mahmoud","year":"2019","unstructured":"Mahmoud S, Gharagozloo M, Simard C, Gris D (2019) Astrocytes maintain glutamate homeostasis in the CNS by controlling the balance between glutamate uptake and release. Cells 8:184. https:\/\/doi.org\/10.3390\/CELLS8020184","journal-title":"Cells"},{"key":"6101_CR194","doi-asserted-by":"publisher","unstructured":"Zhou X, Lu J, Wei K, Wei J, Tian P, Yue M, Wang Y, Hong D, et al. (2021) Neuroprotective effect of ceftriaxone on MPTP-induced Parkinson\u2019s disease mouse model by regulating inflammation and intestinal microbiota. Oxid Med Cell Longev 2021:9424582. https:\/\/doi.org\/10.1155\/2021\/9424582","DOI":"10.1155\/2021\/9424582"},{"key":"6101_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/J.BRAINRESBULL.2025.111349","volume":"225","author":"NH Almohmadi","year":"2025","unstructured":"Almohmadi NH, Al-kuraishy HM, Al-Gareeb AI, Albuhadily AK, Abdelaziz AM, Jabir MS, Alexiou A, Papadakis M, et al. (2025) Glutamatergic dysfunction in neurodegenerative diseases focusing on Parkinson\u2019s disease: role of glutamate modulators. Brain Res Bull 225:111349. https:\/\/doi.org\/10.1016\/J.BRAINRESBULL.2025.111349","journal-title":"Brain Res Bull"},{"key":"6101_CR196","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/J.NURT.2008.02.003","volume":"5","author":"AL Peterson","year":"2008","unstructured":"Peterson AL, Nutt JG (2008) Treatment of Parkinson\u2019s disease with trophic factors. Neurotherapeutics 5:270\u2013280. https:\/\/doi.org\/10.1016\/J.NURT.2008.02.003","journal-title":"Neurotherapeutics"},{"key":"6101_CR197","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/S00441-020-03269-8","volume":"382","author":"DM Gash","year":"2020","unstructured":"Gash DM, Gerhardt GA, Bradley LH, Wagner R, Slevin JT (2020) GDNF clinical trials for Parkinson\u2019s disease: a critical human dimension. Cell Tissue Res 382:65\u201370. https:\/\/doi.org\/10.1007\/S00441-020-03269-8","journal-title":"Cell Tissue Res"},{"key":"6101_CR198","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/J.STEM.2015.09.012","volume":"17","author":"L Zhang","year":"2015","unstructured":"Zhang L, Yin JC, Yeh H, Ma NX, Lee G, Chen XA, Wang Y, Lin L, et al. (2015) Small molecules efficiently reprogram human astroglial cells into functional neurons. Cell Stem Cell 17:735. https:\/\/doi.org\/10.1016\/J.STEM.2015.09.012","journal-title":"Cell Stem Cell"},{"key":"6101_CR199","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/MT.2011.249","volume":"20","author":"A Drinkut","year":"2011","unstructured":"Drinkut A, Tereshchenko Y, Schulz JB, B\u00e4hr M, K\u00fcgler S (2011) Efficient gene therapy for Parkinson\u2019s disease using astrocytes as hosts for localized neurotrophic factor delivery. Mol Ther 20:534. https:\/\/doi.org\/10.1038\/MT.2011.249","journal-title":"Mol Ther"},{"key":"6101_CR200","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/J.TINS.2024.10.006","volume":"48","author":"LC Duret","year":"2025","unstructured":"Duret LC, Nagoshi E (2025) The intertwined relationship between circadian dysfunction and Parkinson\u2019s disease. Trends Neurosci 48:62\u201376. https:\/\/doi.org\/10.1016\/J.TINS.2024.10.006","journal-title":"Trends Neurosci"},{"key":"6101_CR201","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2024.1464595","volume":"18","author":"K Xu","year":"2024","unstructured":"Xu K, Zhang Y, Shi Y, Zhang Y, Zhang C, Wang T, Lv P, Bai Y, et al. (2024) Circadian rhythm disruption: a potential trigger in Parkinson\u2019s disease pathogenesis. Front Cell Neurosci 18:1464595. https:\/\/doi.org\/10.3389\/fncel.2024.1464595","journal-title":"Front Cell Neurosci"},{"key":"6101_CR202","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/J.FREERADBIOMED.2018.09.002","volume":"133","author":"T Ishii","year":"2019","unstructured":"Ishii T, Warabi E, Mann GE (2019) Circadian control of BDNF-mediated Nrf2 activation in astrocytes protects dopaminergic neurons from ferroptosis. Free Radic Biol Med 133:169\u2013178. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2018.09.002","journal-title":"Free Radic Biol Med"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06101-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06101-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06101-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T21:35:06Z","timestamp":1787175306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-06101-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":202,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6101"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-06101-6","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declare they have no need for ethics approval and consent to participate, as it is not applicable to this paper.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no conflicts of interest or relevant financial disclosures for this manuscript.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"845"}}